Searchable abstracts of presentations at key conferences on calcified tissues
Previous issue | Volume 3 | ECTS2014 | Next issue

European Calcified Tissue Society Congress 2014

Prague, Czech Republic
17 May 2014 - 20 May 2014

Card image cap
European Calcified Tissue Society Annual Congress, 17 - 20 May 2014; Prague, Czech Republic

ba0003lb1 | (1) | ECTS2014

Endochrondral ossification, mesenchymal stem cell and Wnt pathway specific loci predict differential skeletal effects in high bone mass

Gregson Celia , Kemp John , Marshall Mhairi , Smith George Davey , Brown Matthew , Duncan Emma , Tobias Jon

Extreme high bone mass (HBM) may be monogenic (e.g. LRP5 mutations) or polygenic, due to variants in the same genes determining bone mineral density (BMD) as found in the general population. We aimed to determine how variation in established BMD loci, in different functional pathways, explains the HBM phenotype.241 unexplained HBM cases (lumbar spine(LS)1+total hip(TH) Z-scores≥+4.4) were recruited from 15 UK centres, by screening...

ba0003lb2 | (1) | ECTS2014

Bisphosphonates for osteoporosis and risk of breast cancer: misleading results from observational studies

Cummings Steven R , Hue Trisha , Cauley Jane A , Bauer Doug C , Ensrud Kristine E , Barrett-Connor Elizabeth , Black Dennis M

Purpose: To test whether bisphosphonates for osteoporosis reduce the risk of breast cancer.Background: Observational studies and meta-analyses find that women taking bisphosphonates have about a 1/3rd reduction in risk of breast cancer as soon as 1 year of treatment. This is plausible because bisphosphonates have in vitro anti-tumor activity and high doses of zoledronate reduce recurrence in women with breast cancer. However, observational studi...

ba0003lb3 | (1) | ECTS2014

Meta-analysis of randomised trials shows limited evidence to support the use of bisphosphonates for fracture prevention in osteogenesis imperfecta

Hald Jannie , Langdahl Bente , Evangelou Evangelos , Ralston Stuart

Osteogenesis imperfecta refers to a group of inherited disorders characterised by increased bone fragility, low bone mass and fragility fractures. Most patients carry mutations in the genes that encode type I collagen or other proteins involved in its post-translational modification. Bisphosphonates are widely used in the treatment of osteogenesis imperfecta but clinical trials have been powered to detect effects on BMD rather than fracture. In order to gain better understandi...

ba0003lb4 | (1) | ECTS2014

History of cardiovascular events and risk factors for cardiovascular events among osteoporotic patients initiating strontium ranelate in the UK

Yu Jingbo , Tang Jackson , Li Zhiyi , Sazonov Vasilisa , Sajjan Shiva , Lion Michaela , O'Regan Christopher

Objective: To estimate the proportion of patients who experienced cardiovascular (CV) events or were at risk for CV events prior to initiation of strontium ranelate among osteoporotic (OP) patients.Methods: This was a retrospective database analysis using the Clinical Practice Research Datalink (CPRD) database. Patients were included if they had ≥1 prescription (Rx) of strontium from 9/1/2008 to 8/31/2013, were aged ≥50 years as of the index ...

ba0003lb5 | (1) | ECTS2014

Early exposure to extra vitamin D from food fortification and bone fractures in adolescents: results from the D-tect study

Handel Mina Nicole , Raymond Kyle , Cooper Cyrus , Heitmann Berit Lilienthal , Abrahamsen Bo

Background: Improving the general population’s vitamin D status through food fortification is part of an ongoing debate. Vitamin D status during pregnancy may influence the long-term bone health of offspring; yet conflicting results have been reported and none of the studies have examined paediatric fracture as outcome.Method: The influence of extra vitamin D exposure during prenatal life and risk of fracture during adolescence was determined by com...